BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.

Autres langues Biohaven Pharmaceutical Holding Company Ltd.

Actions

BHVN

VGG111961055

Marché Fermé - Nyse Autres places de cotation 22:00:02 02/05/2024			Varia. 5j.	Varia. 1 janv.
39,9 ^USD	-0,70 %		+3,77 %	-73,72 %

25/04	Un initié de Biohaven a acheté des actions d'une valeur de 999 169 $, selon un récent dépôt auprès de la SEC	MT
23/04	Les actions de Biohaven augmentent après la clôture de l'offre publique, la divulgation de l'achat d'actions par le PDG	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Biohaven Insider Bought Shares Worth $999,169, According to a Recent SEC Filing	25/04
Biohaven Shares Rise After Closing of Public Offering, Disclosure of Stock Purchase by CEO	23/04
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares	23/04
Biohaven Insider Bought Shares Worth $7,999,961, According to a Recent SEC Filing	23/04
Biohaven Insider Bought Shares Worth $4,999,991, According to a Recent SEC Filing	23/04
Biohaven Announces Pricing of $230 Million Public Offering of Common Shares	19/04
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	18/04
Biohaven Prices $230 Million Public Share Offering	18/04
Biohaven Launches $200 Million Common Stock Offering	17/04
Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology Annual Meeting and Provides Other Business Updates	15/04
Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments	01/03
Biohaven Q4 Non-GAAP Net Loss Widens, Shares Fall After-Hours	29/02
Biohaven Highlights Progress across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference	09/01
Biohaven to Present at the 42nd Annual J.P. Morgan Healthcare Conference	03/01
Biohaven Insider Sold Shares Worth $459,663, According to a Recent SEC Filing	02/01
Biohaven Presents Expanded EEG and Safety Data for BHV-7000 at the American Epilepsy Society Annual Meeting	04/12
Biohaven Reports Third Quarter 2023 Financial Results and Recent Business Developments	15/11
Biohaven Pharmaceutical Q3 Net Loss Narrows	14/11
Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek	17/10/23
Biohaven Pharmaceutical Says Obesity Treatment Candidate Reduces Fat, Improves Lean Mass	16/10/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Biohaven Pharmaceutical Holding Company Ltd.

Actions

BHVN

VGG111961055

Autres langues

Filtres